Belite Bio (BLTE) Projected to Release Earnings on Monday

Belite Bio (NASDAQ:BLTE) is expected to be posting its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect Belite Bio to announce earnings of ($0.73) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

Belite Bio (NASDAQ:BLTE) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.26. On average, analysts expect Belite Bio to post $-3 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Belite Bio Trading Down 1.5%

BLTE traded down $2.34 during trading on Monday, hitting $156.27. The stock had a trading volume of 9,353 shares, compared to its average volume of 193,487. The firm has a market cap of $6.26 billion, a PE ratio of -61.78 and a beta of -1.22. Belite Bio has a 12 month low of $60.00 and a 12 month high of $200.00. The company has a 50 day simple moving average of $147.97 and a 200-day simple moving average of $159.35.

Insider Buying and Selling at Belite Bio

In other news, insider Nathan L. Mata sold 1,000 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $155.50, for a total value of $155,500.00. Following the sale, the insider owned 1,666 shares in the company, valued at approximately $259,063. The trade was a 37.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Hendrik Peter Scholl sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $145.24, for a total transaction of $1,452,400.00. Following the sale, the insider directly owned 15,000 shares in the company, valued at $2,178,600. This represents a 40.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 21,666 shares of company stock valued at $3,115,638 over the last quarter. Corporate insiders own 13.29% of the company’s stock.

Institutional Trading of Belite Bio

Several institutional investors and hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd boosted its position in shares of Belite Bio by 28,200.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock worth $45,000 after purchasing an additional 282 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in Belite Bio in the fourth quarter worth $108,000. Bank of America Corp DE boosted its position in shares of Belite Bio by 28.1% during the third quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock worth $87,000 after purchasing an additional 257 shares in the last quarter. Brooklyn Investment Group acquired a new position in shares of Belite Bio in the 4th quarter valued at $287,000. Finally, Royal Bank of Canada bought a new stake in shares of Belite Bio in the 4th quarter valued at $334,000. Institutional investors own 0.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on BLTE. HC Wainwright reissued a “buy” rating on shares of Belite Bio in a research report on Wednesday, July 22nd. Zacks Research raised Belite Bio from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 20th. Truist Financial set a $217.00 price target on Belite Bio in a report on Friday, May 22nd. Mizuho reduced their price objective on Belite Bio from $223.00 to $215.00 and set an “outperform” rating for the company in a research report on Tuesday, May 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Belite Bio in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $203.00.

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.